arrow
A

Alan D. Irvine

Trinity College Dublin
H指数:85
被引数:3.7万

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Targeted therapies for psoriasis and atopic dermatitis in the context of malignancy: SPIN-FRT recommendations

针对银屑病和特应性皮炎的靶向治疗在恶性肿瘤背景下的应用:SPIN-FRT建议

2026-08-110
PRE
P149 Efficacy of lebrikizumab at 16 weeks: pooled analyses from the ADvocate1 and ADvocate2 phase III trials in adolescent and older adult patients with moderate-to-severe atopic dermatitis

P149 青少年和成年中重度特应性皮炎患者中lebrikizumab 16周疗效:ADvocate1和ADvocate2 III期试验的合并分析

2026-06-260
OAAI
P127 Impact of minimal disease activity on quality of life in patients with atopic eczema: results from the UK-Irish Atopic eczema Systemic TherApy Register (A-STAR)

P127 最小疾病活动度对特应性湿疹患者生活质量的影响:来自英国-爱尔兰特应性湿疹系统性治疗登记系统(A-STAR)的结果

2026-06-260
OAAI
The VASCERN-VASCA diagnostic and management pathways for kaposiform hemangioendothelioma

VASCERN-VASCA 诊断和管理路径,用于卡波西样血管内皮瘤

2025-12-130
OAAI
361 Lebrikizumab Dosed Every 8 Weeks as Maintenance Provides Long-Lasting Response in Patients with Moderate-to-Severe Atopic Dermatitis

361 勒布rikizumab 每8周作为维持剂量使用可为中重度特应性皮炎患者提供长效应答

2025-11-100
PRE
International Multi-Center Case Series of Gestational Dupilumab Exposure in the Treatment of Atopic Dermatitis: Maternal Complications and Fetal Outcomes

国际多中心病例系列研究:妊娠期Dupilumab暴露于特应性皮炎治疗中的母体并发症和胎儿结局

2025-10-290
PRE